tbuckley/cabot-search huggingface dataset:
Biography
Authors: Carl C. Bell
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Death begets failure in the heart
Authors: Roger S.-Y. Foo, Kartik Mani, Richard N. Kitsis
Journal: Journal of Clinical Investigation (2005)

Recently, low — but abnormal — rates of cardiomyocyte apoptosis have been observed in failing human hearts. Genetic and pharmacological studies suggest that this cell death is causally linked to heart failure in rodent models. Herein, we review these data and discuss potential therapeutic implications.
Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non–Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
Journal: Journal of Thoracic Oncology (2017)
Spontaneous regression associated with apoptosis in a patient with acute‐type adult T‐cell leukemia
Authors: Kakushi Matsushita, Naomichi Arima, Hiroshi Fujiwara, Shiroh Hidaka, Hideo Ohtsubo, Kosei Arimura, Toshimasa Kukita, Midori Okamura, Chuwa Tei
Journal: American Journal of Hematology (1999)
Toxoplasmic Lymphadenitis
Authors: T. C. Jones
Journal: JAMA (1965)

Six cases of lymphadenitis due to toxoplasmosis are described. Three of these cases were documented by isolation of the parasite, three others by changes in antibody titers. The clinical picture of lymphadenopathy with varying degrees of fatigue, malaise, and anorexia is discussed in detail. The involvement of skin, heart, and lungs in the adult form of toxoplasmosis is specifically mentioned. Specific laboratory tests and treatment are outlined and the chronic and latent aspects of the illness are considered. The importance of the parasite as a common cause of lymphadenopathy is emphasized.
Reimbursement Discrimination Repeal Bill Introduced
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drug Prophylaxis for Arterial Thromboembolism—1981
Authors: Stanford Wessler
Journal: JAMA (1981)

Recent multicenter clinical trials using platelet-suppressive agents for the secondary prevention of myocardial infarction have yielded inconclusive results, although some of the data suggest possible benefits. For transient ischemic attacks, after carotid artery surgery has been eliminated as an option, aspirin is the drug of choice for men; for women, and for men in whom aspirin fails, warfarin sodium should be considered. Warfarin is indicated after insertion of cardiac prosthetic disk valves, and if systemic emboli occur, dipyridamole should be added. Patients with atrial fibrillation should be treated prophylactically with coumarin agents, but only if underlying organic heart disease is demonstrable. (<i>JAMA</i>1981;246:2484-2487)
Modern Epidemiology
Authors: Steven D. Helgerson
Journal: JAMA (1987)

<i>Modern Epidemiology</i>is a good book. In a thorough, usually clear manner, Rothman presents the topics an epidemiologist must understand to practice and teach epidemiology correctly. The first third of the book concerns basic epidemiologic concepts such as the meaning of causal inference, ways to measure and assess disease frequency, and strategies for choosing and using types of epidemiologic studies. The discussion of these basic concepts is not superficial; in fact, many public health specialists would benefit from careful reading of these insight-filled chapters. Chapter 5, which describes direct and indirect standardization and compares the two techniques, is an especially good example of the author's ability to select contemporary illustrations and develop thought-provoking critique. His mastery of epidemiologic concepts is evidenced further in the discussion of bias and confounding in chapter 7. The final two thirds of the book focuses on data analysis. The chapters are not those of a
Steroid Sulfotransferases
Authors: CHARLES A. STROTT
Journal: Endocrine Reviews (1996)

I. IntroductionTHE discovery that steroids are excreted in urine as conjugates of sulfuric acid was made more than 50 yr ago (1, 2). The enzymes responsible for forming the steroid sulfoconjugates, however, were not initially examined until almost 20 yr later (3–6). After that, interest rose rapidly, resulting in considerable progress for this important and intriguing metabolic process. The importance pertains to the striking change in the physical, chemical, and biological properties that occurs on formation of steroid sulfoconjugates; the fascination relates to the fact that the biological significance of this process, for the most part, remains a conundrum. It is especially enigmatic in steroidogenic tissues such as the adrenal, ovary, and testis. The fact is, 40 yr of investigation, notwithstanding, neither the biochemistry nor the biological import of steroid sulfonation is well understood. The enzymology, although appearing simple in principle, is complex and although interesting functional implications have been put forth, the biology of steroid sulfonation has been difficult to assess and thus remains largely speculative.
Abstract 947: Dpp10 - A New Putative Regulatory β-subunit Of I <sub>to</sub> In Failing And Non-failing Human Heart
Authors: Susanne Radicke, Diego Cotella, Alessio Bortoluzzi, Ursula Ravens, Daniele Sblattero, Erich Wettwer
Journal: Circulation (2007)

Background: Recently we reported that the dipeptidyl-aminopeptidase-like protein DPP6 serves as a regulatory β-subunit for cardiac Kv4.3 channels. DPP6 is up-regulated in human failing hearts in which Kv4.3 and the β-subunit KChIP2 are down-regulated. Here, we provide evidence for the presence of a new member of this protein family, i.e. DPP10, in failing and non-failing human hearts and investigate the role of this putative β-subunit in regulating transient outward current. Methods: mRNA was extracted from samples of 5 failing and 5 non-failing human hearts and quantified by realtime PCR. Functional interaction of DPP10 and Kv4.3 was studied in co-expression experiments (Chinese hamster ovary CHO cells) with standard voltage clamp techniques. Results: Expression level of DPP10 was 85±13 fg/ng in failing and 33±6 fg/ng total RNA in non-failing hearts (P&lt;0.01), amounting to a 2.6fold reduction. In comparison, DPP6 was up-regulated 1.3fold (P&lt;0.001). After co-expression of Kv4.3 and DPP10 in CHO cells, channel complexes were verified in the plasma membrane by immunostaining, suggesting proper trafficking as with co-expression of Kv4.3 and KChIP2. Expression of Kv4.3 alone failed to yield I to current, but robust I to amplitudes were measured after co-expression of Kv4.3 and DPP10, DDP6, or KChIP2. Compared with the conventional co-expression combination of Kv4.3 and KChIP2, kinetics of I to inactivation were accelerated in Kv4.3 plus DPP10 channels (τ fast : 56± 3 ms and 5.9±0.4 ms, respectively; P&lt;0.01), however, recovery from inactivation was not affected (τ rec : 53± 7 ms vs. 58±13 ms). Co-expression of Kv4.3 with KChIP2 plus DPP10 maintained rapid inactivation of I to (τ fast 8±1ms), but enhanced recovery kinetics (τ rec : 13±2 ms, P&lt;0.001). The role of glycosylation for channel kinetics was studied with the glycosylation inhibitor tunicamicin (10 μg/ml; 24h). In the presence of tunicamicin, I to inactivation and recovery were slowed (τ fast 51± 4 ms and τ rec : 42±3 ms), suggesting importance of glycosylation for channel function. Kinetics were similarly slowed when extracellular domain of DDP10 was deleted (τ fast : 48±5 ms, τ rec : 30± 4 ms). Conclusion: DPP10, like DPP6 and KChIP2, contributes to regulation of I to in normal and diseased human hearts.
Remarks on the Various Surgical Procedures Devised for the Relief or Cure of Trigeminal Neuralgia (Tic Douloureux)
Authors: V. Horsley
Journal: BMJ (1891)

11S9fication of a disease-producing microphyte is the faculty of living and multiplying in the living tissue, the researches of recent years have taucght us that its poisonousness is even more essential than its adaptedness to a living nutritive me- dium; so much so that the damage which it thereby inflicts on its living environment is a means by which it modifies that environment for its own advantage.We have further seen that the contest whiclh takes place in the organism be- tween invading microphytes and the living elements of the
Cardiac Disturbances as the Result of Exhaustion
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Low Muscarinic Receptor Binding in Prefrontal Cortex From Subjects With Schizophrenia: A Study of Brodmann's Areas 8, 9, 10, and 46 and the Effects of Neuroleptic Drug Treatment
Authors: J. M. Crook
Journal: American Journal of Psychiatry (2001)

OBJECTIVE: Aberrant cholinergic inputs and synaptic neurotransmission in the prefrontal cortex induce cognitive impairment, which is a central feature of schizophrenia. Postsynaptic excitatory muscarinic cholinergic M1 and M4 receptors are the major cholinoceptive targets in the prefrontal cortex and hence may be involved in the pathology and/or pharmacotherapeutics of schizophrenia. METHOD: Using quantitative autoradiography, the authors analyzed the binding of the M1/M4 receptor selective antagonist [3H]pirenzepine in prefrontal cortex (Brodmann's areas 8, 9, 10, and 46) from schizophrenia patients who had (N=6) or had not (N=11) been treated with the anticholinergic agent benztropine mesylate and from normal comparison subjects (N=20). Moreover, preliminary studies of [3H]pirenzepine binding in rat frontal cortex following administration of antipsychotic drugs or benztropine mesylate were performed. RESULTS: Relative to those of comparison subjects, the mean levels of [3H]pirenzepine binding were significantly lower in Brodmann's areas 9 and 46 of the schizophrenia patients not treated with benztropine mesylate (18% lower in Brodmann's area 9 and 21% lower in Brodmann's area 46) and in all four examined regions of the patients who had received benztropine (51%–64% lower). Antipsychotic or anticholinergic drugs tended to increase or have no effect on the density of [3H]pirenzepine-labeled receptors in rat frontal cortex. CONCLUSIONS: Because M1 and M4 receptors are critical to the functions of prefrontal cortical acetylcholine, the present findings suggest a functional impairment in cholinergic neurotransmission in schizophrenia and the possibility that muscarinic receptors are involved in the pharmacotherapeutics of the disorder.
Molecular Epidemiology of Aflatoxin Exposures: Validation of Aflatoxin-N7-Guanine Levels in Urine As a Biomarker in Experimental Rat Models and Humans
Authors: John D. Groopman, Christopher P. Wild, Julia Hasler, Chen Junshi, Gerald N. Wogan, Thomas W. Kensler
Journal: Environmental Health Perspectives (1993)

Human epidemiology and experimental animal data have provided the statistical association and biological information necessary to propose that aflatoxins are risk factors for human liver cancer. As liver cancer causes at least 200,000 deaths per year, prevention measures must be developed to ameliorate this nearly always fatal disease. Preventive strategies will be facilitated by the identification of individuals at high risk. It is the goal of the molecular dosimetry field to provide facile and accurate biomarkers to identify people at high risk for carcinogen exposure and consequent adverse health effects. We have developed methods to defect the major aflatoxin DNA adduct, aflatoxin N7-guanine (AFB-N7-guanine), in urine, examined the dose-response characteristics in people living in China and The Gambia, and have found an excellent association of this biomarker with exposure. In addition to exposure studies in people, our laboratories have monitored AFB-N7-guanine excretion in the urine of rats whose risk for developing cancer has been modulated with dietary chemoprotective agents such that independent groups of animals receiving the same dosage of aflatoxin B1 were at either high or low risk for tumorigenesis. The production of DNA damage by aflatoxins is not the exclusive mechanism for liver cancer. Many other factors, including hepatitis B virus, cell proliferation, and nutritional status, can exert strong modification effects in human disease. Thus, molecular epidemiological investigations that examine only one biomarker may greatly underestimate or overestimate the risk for an individual.(ABSTRACT TRUNCATED AT 250 WORDS)
Physiological Basis and Interpretation of Indices of Pulmonary Mechanics
Authors: Jeffrey M. Drazen
Journal: Environmental Health Perspectives (1984)

Tests of pulmonary mechanical function provide information about the state of the lungs, both airways and parenchyma. This information can be extracted from measurements made in experimental animals, especially the combined determination of pulmonary resistance and dynamic compliance. This report discusses the rationale upon which effects of an intervention on the lung periphery can be distinguished from those on more central airways. Further, practical considerations involved in making these measurements are discussed.
Rubaiyat of Doc Sifers.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The adolescent viewpoint. Implications for access and prevention
Authors: T. L. Cheng
Journal: JAMA (1995)

Although most adolescents are healthy, adolescence is the age group in which mortality rates have increased most dramatically in recent decades.<sup>1,2</sup>Many engage in risky behaviors that can affect their health. Unintentional injury, homicide, and suicide are the leading causes of death for teens, and as many as one in four adolescents are at risk for substance abuse, sexually transmitted diseases, early unintended pregnancy, and school failure.<sup>3,4</sup>These preventable health problems make the availability of certain health services—including reproductive health services, diagnosis and treatment of sexually transmitted disease and human immunodeficiency virus (HIV), and mental health and substance abuse services—critically important for this age group. When these services are not accessible to youth, the result is missed opportunities for prevention. See also p 1913. Although American adolescents face major threats to their health, formidable barriers exist in seeking care. Adolescents and young adults have the lowest rate of
Abstract 4321: Epigenetic regulation of TP73 expression in HCC and GI cancer
Authors: Zhixing Yao, Cristina Di Poto, Habtom W. Ressom, Zaki A. Sherif
Journal: Cancer Research (2019)

Abstract Tumorigenesis results from an accumulation of mutational and epigenetic changes that alter normal cell growth and survival pathways. TP73 is the homologue of the master tumor suppressor TP53 involved in cellular responses to stress and development. The TP73 gene encodes two different protein isoforms, TAp73 and ΔNp73, and maps to a region on chromosome 1p36 that is frequently deleted in neuroblastoma and other tumors, and is thought to contain multiple tumor suppressor genes. However, the analysis of p73-knockout mice yielded conflicting results with respect to tumor suppression. World-wide efforts in sequencing the TP73 gene in patient tumor samples have not provided evidence for genetic alterations as a common cause of TP73 inactivation in human cancer. The role of TP73 in tumorigenesis has remained elusive to date. In this study, we isolated two stem cell lines from normal young and old human liver tissues to determine TP73 expression in normal human liver stem cell and hepatocellular cancer (HCC) cell lines (HepG2, SNU398, SNU449 &amp; SNU475), gastrointestinal cancer (GI) cell lines (Caco2 &amp; HCT116) and a normal skin fibroblast cell line (HS27). The results show that TP73 only expresses in cancer cell lines. Further immunohistochemistry studies on human normal liver tissues as well as adjacent normal and cancerous liver tissues from HCC patients confirm that TP73 only expresses in the cancerous tissues. Moreover, methylation-specific PCR and bisulfite sequencing studies revealed that TP73 promoter is activated only in cancer cell lines by DNA methylation. Furthermore, ChIP assay results demonstrated that CTCF (a chromosomal networking protein CCCTC binding factor) binds to TP73 promoter and regulates TP73 expression. Our observation may prove significant for the development of future therapeutic and diagnostic applications. Citation Format: Zhixing Yao, Cristina Di Poto, Habtom W. Ressom, Zaki A. Sherif. Epigenetic regulation of TP73 expression in HCC and GI cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4321.
Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial.
Authors: C. Pan, P. Ghosh, P. Lara, D. Robles, L. Beckett, R. de Vere White
Journal: Journal of Clinical Oncology (2011)

157 Background: Multiple signaling pathways are involved in the development of CRPC. We previously showed that the mTOR pathway is activated in CRPC cell lines while inhibition of this pathway results in upregulation of androgen receptor (AR) signaling (Wang et al, Oncogene. 2008). Simultaneous blockade of the mTOR and AR pathways synergize in inducing PCa cell death and delaying tumor formation in mouse models. We hypothesize that simultaneous blockade of the AR and mTOR pathways in CRPC patients with bicalutamide and everolimus will result in improved efficacy compared to bicalutamide alone. Methods: A phase II clinical trial with a lead-in safety phase was designed to determine the efficacy and tolerability of the bicalutamide and everolimus combination in CRPC patients compared with bicalutamide alone. Patients must have histologically confirmed disease and demonstrated disease progression (either by PSA or radiographically) while on androgen deprivation therapy. At the lead-in phase, all patients receive both agents. At the phase II stage, patients are randomized to bicalutamide +/− everolimus. The primary endpoint is PSA response. The second endpoints include progression-free survival, time-to-treatment failure, overall survival and toxicity. Here, we report the results of the lead-in phase. Results: Eight patients were recruited at the lead-in phase. The bicalutamide/everolimus combination was well tolerated with no unexpected toxicities. Six of 8 patients have had PSA response after at least 8 weeks of therapy and the remaining two patients had stable PSA response. The median time to disease progression was 6.8 months. Nine patients have been recruited at the phase II stage so far. This clinical trial is being subcontracting to the other sites of the California Cancer Consortium. Tumor and blood specimens are being collected for molecular correlative studies of mTOR pathway markers. Conclusions: The rational combination of bicalutamide and everolimus appears to have promising anti-tumor activity and an acceptable toxicity profile. The randomized phase of the clinical trial is currently ongoing and will be reported. Supported by Novartis. [Table: see text]